Low dose naloxone provides an abuse deterrent effect to buprenorphine

November 6, 2015

Webster LR, Smith MD, Unal C, Finn A (Source: Journal of Pain Research) MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.

Read the full article →

Alcohol and tobacco use in cocaine-dependent participants provided treatment with buprenorphine/naloxone and naltrexone

November 3, 2015

Aims: Many individuals with cocaine use disorders also use alcohol and tobacco. A recent study conducted by NIDA’s Clinical Trials Network investigated pharmacotherapy for treatment of cocaine use disorders and also assessed alcohol and tobacco use. (Source: Drug and Alcohol Dependence)

Read the full article →

Intranasal buprenorphine alone and in combination with naloxone: Reinforcing efficacy and abuse liability in physically dependent opioid abusers

November 3, 2015

Aims: Buprenorphine/naloxone (BUP/NX) was designed to prevent misuse by the intravenous (IV) route, as high naloxone IV bioavailability may precipitate withdrawal. We previously demonstrated that intranasal (IN) administration of BUP/NX results in appreciable absorption of naloxone. The present study explored whether IN BUP/NX has lower abuse potential and reinforcing efficacy compared to IN BUP alone […]

Read the full article →

The Cocaine Use Reduction with Buprenorphine study: Cocaine use findings

November 3, 2015

Aims: The Cocaine Use Reduction with Buprenorphine (CURB) study, conducted under the National Drug Abuse Treatment Clinical Trials Network, investigated the safety and effectiveness of buprenorphine/naloxone (BUP, as Suboxone®) provided on a platform of extended-release injectable naltrexone (XR-NTX, as Vivitrol®) for reducing cocaine use in participants who met DSM- IV criteria for cocaine dependence and […]

Read the full article →

Pilot study of atomoxetine for BUP/NX-maintained patients with co-occurring opioid and ATS use disorder

November 3, 2015

Aims: To evaluate the tolerability, acceptability, and potential efficacy of the selective norepinephrine transporter inhibitor atomoxetine for treating amphetamine-type stimulant (ATS) use disorder in patients receiving buprenorphine/naloxone (BUP/NX). (Source: Drug and Alcohol Dependence)

Read the full article →

The problem with prescription painkillers

October 27, 2015

Pain. It’s a nearly unavoidable part of the human experience. Whether it comes as the result of an injury or accident, surgery, or a health issue such as a headache or infection, arthritis, or fibromyalgia, pain can interfere with the ability to sleep, work, and enjoy life. There are many ways to treat pain. Opioid […]

Read the full article →

The problem with prescription painkillers

October 27, 2015

Pain. It’s a nearly unavoidable part of the human experience. Whether it comes as the result of an injury or accident, surgery, or a health issue such as a headache or infection, arthritis, or fibromyalgia, pain can interfere with the ability to sleep, work, and enjoy life. There are many ways to treat pain. Opioid […]

Read the full article →

Opioid Addiction Treatment in the eu5: Market Access Levers for Emerging Brands Entering a Generic Market

October 24, 2015

Standard-of-care for opioid addiction is substitution therapy with methadone, buprenorphine, or buprenorphine/naloxone. As EU5 healthcare budgets tighten, this study explored how emerging brands may gain a foothold in this increasingly generic market, as payers and prescribers balance clinical need with limited funds. (Source: Value in Health)

Read the full article →

Cost-Effectiveness Analysis of Opioid Substitution Treatment in Slovenia

October 24, 2015

We analyzed cost effectiveness of buprenorphine/naloxone combination and sustained release (SR) morphine when compared to methadone in patients treated for opioid dependence in Slovenia. To compare the expected costs of treatment with buprenorphine/naloxone combination and SR morphine, we also performed cost-minimization analysis. (Source: Value in Health) MedWorm Sponsor Message: Directory of the best January Sales […]

Read the full article →

Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir/Ritonavir (2D Regimen).

October 18, 2015

Authors: Badri PS, Dutta S, Wang H, Podsadecki TJ, Polepally AR, Khatri A, Zha J, Chiu YL, Awni WM, Menon RM Abstract The 2D regimen of ombitasvir and paritaprevir (administered with low-dose ritonavir) is being developed for treatment of genotype subtype 1b and genotypes 2 and 4 chronic hepatitis C virus (HCV) infection. Drug-drug interactions […]

Read the full article →

← Previous Entries

Next Entries →